Panobinostat

A potent inhibitor of class I and II HDACs [1]. Cotreatment with panobinostat and an HSP90 inhibitor caused synergistic apoptosis in human CML-BC and AML cells [2]. A potent antimyeloma agent that overcomes drug resistance [3].

References:

1) Geng et al. (2006), Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer;  Cancer Res., 66 11298

2) George et al. (2005), Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3;  Blood, 105 1768

3) Maiso et al. (2006), The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance;  Cancer Res., 66 5781